NCT02268253 2025-01-06Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)Stemline Therapeutics, Inc.Phase 1/2 Completed82 enrolled 15 charts
NCT02113982 2024-08-01Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid LeukemiaStemline Therapeutics, Inc.Phase 1/2 Completed138 enrolled 23 charts 1 FDA